drugset
Drugs / PF-06651600 Induction Dose
last change Apr 2023 re-read 3 minutes ago

PF-06651600 Induction Dose

Small molecule targets JAK3, TEC via inhibition

Developed for
alopecia areata
Investigated by
Pfizer

Trials 1

today NCT03732807 · Ph 2/3
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT03732807 Dec 2018 → Dec 2020 alopecia areata Pfizer Completed Met primary

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as PF-06651600 Induction Dose ClinicalTrials.gov intervention name — accepted as the source's own label NCT03732807 ↗
Action Inhibit “an oral, selective dual JAK3/TEC family kinase inhibitor” PMID 37062298 ↗ Apr 2023
Modality Small molecule “an oral, selective dual JAK3/TEC family kinase inhibitor” PMID 37062298 ↗ Apr 2023
Route Oral “Oral tablets taken once daily (QD)” NCT03732807 ↗
Target JAK3 “an oral, selective dual JAK3/TEC family kinase inhibitor” PMID 37062298 ↗ Apr 2023
Target TEC “an oral, selective dual JAK3/TEC family kinase inhibitor” PMID 37062298 ↗ Apr 2023